509 related articles for article (PubMed ID: 34873640)
1. Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells.
Khare P; Dave KM; Kamte YS; Manoharan MA; O'Donnell LA; Manickam DS
AAPS J; 2021 Dec; 24(1):8. PubMed ID: 34873640
[TBL] [Abstract][Full Text] [Related]
2. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
[TBL] [Abstract][Full Text] [Related]
4. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
5. Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations.
Wang X; Yu B; Ren W; Mo X; Zhou C; He H; Jia H; Wang L; Jacob ST; Lee RJ; Ghoshal K; Lee LJ
J Control Release; 2013 Dec; 172(3):690-8. PubMed ID: 24121065
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanoparticle-mediated drug delivery to the brain.
Khare P; Edgecomb SX; Hamadani CM; Tanner EEL; S Manickam D
Adv Drug Deliv Rev; 2023 Jun; 197():114861. PubMed ID: 37150326
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge.
Huang X; Chau Y
Mol Pharm; 2021 Jan; 18(1):377-385. PubMed ID: 33295773
[TBL] [Abstract][Full Text] [Related]
8. Lipidoid nanoparticles increase ATP uptake into hypoxic brain endothelial cells.
Khare P; Conway JF; S Manickam D
Eur J Pharm Biopharm; 2022 Nov; 180():238-250. PubMed ID: 36265829
[TBL] [Abstract][Full Text] [Related]
9. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
[TBL] [Abstract][Full Text] [Related]
10. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
11. Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery.
Da Silva Sanchez AJ; Zhao K; Huayamares SG; Hatit MZC; Lokugamage MP; Loughrey D; Dobrowolski C; Wang S; Kim H; Paunovska K; Kuzminich Y; Dahlman JE
J Control Release; 2023 Jan; 353():270-277. PubMed ID: 36423872
[TBL] [Abstract][Full Text] [Related]
12. Lipid nanoparticles for hepatic delivery of small interfering RNA.
Yu B; Hsu SH; Zhou C; Wang X; Terp MC; Wu Y; Teng L; Mao Y; Wang F; Xue W; Jacob ST; Ghoshal K; Lee RJ; Lee LJ
Biomaterials; 2012 Sep; 33(25):5924-34. PubMed ID: 22652024
[TBL] [Abstract][Full Text] [Related]
13. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
[TBL] [Abstract][Full Text] [Related]
14. Polydispersity characterization of lipid nanoparticles for siRNA delivery using multiple detection size-exclusion chromatography.
Zhang J; Haas RM; Leone AM
Anal Chem; 2012 Jul; 84(14):6088-96. PubMed ID: 22816783
[TBL] [Abstract][Full Text] [Related]
15. A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes.
Ramishetti S; Hazan-Halevy I; Palakuri R; Chatterjee S; Naidu Gonna S; Dammes N; Freilich I; Kolik Shmuel L; Danino D; Peer D
Adv Mater; 2020 Mar; 32(12):e1906128. PubMed ID: 31999380
[TBL] [Abstract][Full Text] [Related]
16. Increasing the siRNA knockdown efficiency of lipid nanoparticles by morphological transformation with the use of dihydrosphingomyelin as a helper lipid.
Hashimoto M; Yonezawa S; Furan S; Nitta C; Maeda N; Tomita K; Yokouchi A; Koide H; Asai T
Biomater Sci; 2023 May; 11(9):3269-3277. PubMed ID: 36939181
[TBL] [Abstract][Full Text] [Related]
17. Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer.
Piao L; Li H; Teng L; Yung BC; Sugimoto Y; Brueggemeier RW; Lee RJ
Nanomedicine; 2013 Jan; 9(1):122-9. PubMed ID: 22542825
[TBL] [Abstract][Full Text] [Related]
18. Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity.
Konca YU; Kirshenbaum K; Zuckermann RN
Int J Nanomedicine; 2014; 9():2271-85. PubMed ID: 24872690
[TBL] [Abstract][Full Text] [Related]
19. Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA.
Sato Y; Matsui H; Sato R; Harashima H
J Control Release; 2018 Aug; 284():179-187. PubMed ID: 29936118
[TBL] [Abstract][Full Text] [Related]
20. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells.
Ferraresso F; Strilchuk AW; Juang LJ; Poole LG; Luyendyk JP; Kastrup CJ
Mol Pharm; 2022 Jul; 19(7):2175-2182. PubMed ID: 35642083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
